PAUL KLAASSEN: Open Payments
NPI 1053313361 · ARKANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$233 in 13 payments from 8 companies in 2025. Trend: 2023 $110 · 2024 $149 · 2025 $233
Food & beverage: $233
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $62 |
| Novo Nordisk Inc | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| Amgen Inc. | 1 | $14 |
| PFIZER INC. | 1 | $14 |
Products named: CAPLYTA, Wegovy, JARDIANCE, FANAPT, TRELEGY ELLIPTA, XIFAXAN, EVENITY, PREVNAR 20.
Industry payments across KS — which companies pay providers there.
